Clinical trial
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in…
NCT00389428 · Jazz Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00389428 |
|---|---|
| Title | Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. |
| Official title | Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies. |
| Lead sponsor | Jazz Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hematologic Neoplasms |
| Intervention type | Drug |
| Interventions | CPX-351 (Cytarabine:Daunorubicin) Liposome Injection |
| Enrollment | 48 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Oct 18, 2006 |
| Last update posted | May 17, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: